ASX:ATXPharmaceuticals, Biotechnology & Life SciencesBiotechnology

AMPLIA THERAPEUTICS ORD

$0.155

$0.010 (6.06%)

Day Range

$0.155 - $0.165

52 Week Range

$0.049 - $0.425

Volume

143.76K

Avg Volume (10D)

1.12M

Market Cap

$79.56M

Price Chart

Market Statistics

Open$0.165

Previous Close$0.165

Day High$0.165

Day Low$0.155

52 Week High$0.425

52 Week Low$0.049

Valuation

Market Cap79.56M

Shares Outstanding513.31M

Price to Book1.79

Trading Activity

Volume143.76K

Value Traded22.59K

Bid$0.150 × 205,404

Ask$0.155 × 67,745

Performance

1 Day-3.23%

5 Day11.11%

13 Week20.00%

52 Week188.46%

YTD0.00%

Technical Indicators

RSI (14)50.35

50-Day SMA$0.159

200-Day SMA$0.152

Amplia Therapeutics Launches New Narmafotinib Ovarian Cancer Study with ANZGOG

Amplia Therapeutics launches PRROSE trial with narmafotinib and ANZGOG in ovarian cancer; 15–20 patients, safety focus, biomarker data.

1 min read

Isla Campbell

Biotechnology

Amplia Therapeutics Halts AMPLICITY Trial Recruitment After Chemo-Related DLTs

Amplia Therapeutics halts AMPLICITY recruitment after DLTs with narmafotinib mFOLFIRINOX; pivots to new combos, delaying readouts and raising investor risk.

1 min read

Isla Campbell

Biotechnology

Amplia Therapeutics Reports Stronger Efficacy and Survival in Pancreatic Cancer Trial

Amplia Therapeutics reports ACCENT trial: 7.8% CR, 35.9% ORR, 11.1-month median OS in pancreatic cancer; trading halt ahead of AACR.

2 min read

Isla Campbell

Biotechnology

Amplia Therapeutics Releases New Topline Data from ACCENT Narmafotinib Pancreatic Cancer Trial

Amplia Therapeutics (ASX: ATX) has released new topline data from an ongoing trial of its best-in-class selective FAK inhibitor narmafotinib on advanced pancreatic cancer. The ACCENT clinical trial is investigating the safety, tolerability, pharmacokinetics and preliminary efficacy of narmafotinib when used in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Latest data to 20 July has […]

2 min read

Imelda Cotton